R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Accrued Liabilities
ÂĄ46.1m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Accrued Liabilities
ÂĄ2.2B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accrued Liabilities
ÂĄ732.6m
CAGR 3-Years
18%
CAGR 5-Years
30%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accrued Liabilities
ÂĄ393.2m
CAGR 3-Years
-1%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accrued Liabilities
ÂĄ346m
CAGR 3-Years
25%
CAGR 5-Years
28%
CAGR 10-Years
46%
W
WuXi XDC Cayman Inc
HKEX:2268
Accrued Liabilities
ÂĄ74.9m
CAGR 3-Years
109%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Accrued Liabilities?
Accrued Liabilities
46.1m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Accrued Liabilities amounts to 46.1m CNY.

What is R&G PharmaStudies Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
4%

Over the last year, the Accrued Liabilities growth was -1%. The average annual Accrued Liabilities growth rates for R&G PharmaStudies Co Ltd have been 4% over the past three years .

Back to Top